Fig. 2From: Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to acceptCost-effectiveness of reservation prices submitted (run two, monotone preferences). REG, regulator; SEL, seller; SoC, standard of care; QoL, quality of life; pref., preferences; ICER, incremental cost-effectiveness ratio; QALM, quality adjusted life monthBack to article page